Program
TS-172
A development code. Also written as “TS-172 20~60 mg/day”, “'TS-172 20~60 mg/day” and “TS-172 20 mg”.
Its studies are mostly in Hyperphosphatemia, led by Taisho Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Taisho Pharmaceutical | 144 open or running | phase 3since Dec 17, 2024 | Jul 5, 2021 | Nov 30, 2026phase 3 · NCT07548840 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 5, 2021First study: phase 1 study in Healthy Adult SubjectsFirst studyNCT04979572 · 41 enrolled · Japan
- Jan 12, 2023Phase 2 study in Hyperphosphatemia Patients on HemodialysisNCT05699239 · 326 enrolled · Japan
- Sep 2, 2024Phase 1 study in Healthy Male SubjectsNCT06596356 · 6 enrolled · Japan
- Dec 17, 2024Phase 3 study in Hyperphosphatemia Patients on HemodialysisNCT06745531 · 101 enrolled · Japan
- Dec 17, 2024Phase 2 study in Hyperphosphatemia Patients on HemodialysisNCT06745518 · 62 enrolled · Japan
- Feb 16, 20253 phase 1 studiesNCT06849778, NCT06837155, NCT06837142
- Jul 17, 2025Phase 1 study in Healthy Adult Male SubjectsNCT07084961 · 16 enrolled · Japan
- Nov 13, 2025Phase 1 study in Patients With Mild or Moderate Hepatic ImpairmentNCT07231029 · 25 enrolled · Japan
- Nov 24, 2025Phase 3 study in Hyperphosphatemia Patients on HemodialysisNCT07285304 · 300 planned · Japan
- Dec 3, 2025Phase 3 study in Hyperphosphatemia Patients on HemodialysisNCT07285291 · 100 planned · Japan
- Apr 16, 20262 phase 3 studiesNCT07548853, NCT07548840
Ahead
- Nov 30, 2026Primary completion: phase 3 study in Hyperphosphatemia Patients on HemodialysisNCT07548840
- Dec 22, 2026Primary completion: phase 3 study in Hyperphosphatemia Patients on HemodialysisNCT07285291
- May 31, 2027Primary completion: phase 3 study in Hyperphosphatemia Patients on Peritoneal DialysisNCT07548853
- Jul 31, 2027Primary completion: phase 3 study in Hyperphosphatemia Patients on HemodialysisNCT07285304
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07548853Hyperphosphatemia Patients on Peritoneal Dialysis · Japan | 3 | Recruiting | May 31, 2027 | 30 |
| NCT07548840Hyperphosphatemia Patients on Hemodialysis · Japan | 3 | Active, not recruiting | Nov 30, 2026 | 34 |
| NCT07285291Hyperphosphatemia Patients on Hemodialysis · Japan | 3 | Recruiting | Dec 22, 2026 | 100 |
| NCT07285304Hyperphosphatemia Patients on Hemodialysis · Japan | 3 | Recruiting | Jul 31, 2027 | 300 |
| NCT07231029Patients With Mild or Moderate Hepatic Impairment · Japan | 1 | Completed | Oct 21, 2026 | 25 |
| NCT07084961Healthy Adult Male Subjects · Japan | 1 | Completed | Sep 11, 2025 | 16 |
| NCT06849778Patients on Hemodialysis · Japan | 1 | Completed | Apr 24, 2025 | 7 |
| NCT06837155Healthy Volunteers · Japan | 1 | Completed | May 20, 2025 | 52 |
| NCT06837142Healthy Male Subjects · Japan | 1 | Completed | Apr 30, 2025 | 30 |
| NCT06745531Hyperphosphatemia Patients on Hemodialysis · Japan | 3 | Completed | Oct 13, 2025 | 101 |
| NCT06745518Hyperphosphatemia Patients on Hemodialysis · Japan | 2 | Completed | Jul 15, 2025 | 62 |
| NCT06596356Healthy Male Subjects · Japan | 1 | Completed | Oct 28, 2024 | 6 |
| NCT05699239Hyperphosphatemia Patients on Hemodialysis · Japan | 2 | Completed | Dec 26, 2023 | 326 |
| NCT04979572Healthy Adult Subjects · Japan | 1 | Completed | Jan 26, 2022 | 41 |
How it is read
Names in the registry
- “TS-172”, 7 entries
- “TS-172 20~60 mg/day”, 3 entries
- “'TS-172 20~60 mg/day”, 1 entry
- “TS-172 20 mg”, 1 entry
- “TS-172 90 mg”, 1 entry
Codes read as this program: TS172.
Conditions, from the studies’ own filings
- Hyperphosphatemia, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.